Cancer Research Center of Toulouse (CRCT) at ESGCT 2026
Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website
Cancer Research Center of Toulouse (CRCT) brings 4 presentations to ESGCT 2026 in Hamburg. Its work centres on pancreatic cancer treated with oncolytic viruses and gene therapy. Lines include how myxoma-derived and parvovirus-based viruses replicate in tumour cells, the host factor they need to get in, and a randomised phase 2 trial of non-viral gene therapy.
| Organization | ESGCT 2026 Attendance |
|---|---|
Cancer Research Center of Toulouse (CRCT) Toulouse, France | |
Poster Wed Oct 28 1:30pm–3:30pm SG33 oncolytic virus derived fom myxoma virus alters mitochondrial function for effective viral replication in pancreatic cancer cells Poster Wed Oct 28 1:30pm–3:30pm TGN46 is a host dependency factor for H-1 parvovirus entry and oncolytic activity in pancreatic cancer Poster Thu Oct 29 2:00pm–4:00pm Directed evolution and combination with immunotherapies improve H-1PV antitumoral efficacy in pancreatic cancer Poster Thu Oct 29 2:00pm–4:00pm Randomized multicentre Phase 2 clinical trial of non-viral gene therapy for pancreatic cancer: clinical and molecular findings |
Instantly find 20 buyers from Cancer Research Center of Toulouse (CRCT)
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction